These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4590072)

  • 1. [Other trials with drug therapy in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2115-7. PubMed ID: 4590072
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug therapy of parkinsonism.
    Yahr MD; Duvoisin RC
    N Engl J Med; 1972 Jul; 287(1):20-4. PubMed ID: 4555145
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical implications of unnatural amino acids and amines.
    Sjoerdsma A
    Fed Proc; 1971; 30(3):908-11. PubMed ID: 4324977
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoamine precursors in the treatment of depression.
    Carroll BJ
    Clin Pharmacol Ther; 1971; 12(5):743-61. PubMed ID: 4936139
    [No Abstract]   [Full Text] [Related]  

  • 5. [Parkinson's disease: current therapeutic aspects].
    Casati C
    Clin Ter; 1971 Jan; 56(1):71-9. PubMed ID: 4944741
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ
    N Y State J Med; 1974 Jan; 74(1):47-51. PubMed ID: 4591989
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of parkinsonism using L-dopa. I].
    Glass J
    Z Arztl Fortbild (Jena); 1972 Dec; 66(23):1195-9. PubMed ID: 4652156
    [No Abstract]   [Full Text] [Related]  

  • 8. [Parkinson's syndrome. 10. Effects of psychopharmacological agents on central monoamine neurons].
    Roos BE
    Lakartidningen; 1970 Oct; 67(42):4840-1. PubMed ID: 4320249
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
    Cotzias GC; Papavasiliou PS; Ginos J; Steck A; Düby S
    Annu Rev Med; 1971; 22():305-26. PubMed ID: 4944422
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 11. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 12. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
    Degkwitz R
    Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
    [No Abstract]   [Full Text] [Related]  

  • 13. [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa].
    Gerstenbrand F; Prosenz P
    Praxis; 1965 Nov; 54(46):1373-7. PubMed ID: 5899418
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-induced relief of experimental tremor in monkeys.
    Goldstein M; Battista AF; Nakatani S; Anagnoste B
    Neurology; 1970 Nov; 20(11):89-95. PubMed ID: 4991252
    [No Abstract]   [Full Text] [Related]  

  • 15. Psychopharmacology. Yesterday, today and tomorrow: a point of view.
    Stancer HC
    Can Psychiatr Assoc J; 1973 Oct; 18(5):371-6. PubMed ID: 4583435
    [No Abstract]   [Full Text] [Related]  

  • 16. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 17. Parkinsonism and DOPA.
    Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB
    Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342
    [No Abstract]   [Full Text] [Related]  

  • 18. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of parkinsonian akinesia].
    Travenets IA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(5):703-6. PubMed ID: 5998829
    [No Abstract]   [Full Text] [Related]  

  • 20. The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
    Dandiya PC; Bhargava LP
    Arch Int Pharmacodyn Ther; 1968 Nov; 176(1):157-67. PubMed ID: 5709781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.